ELCC 2023: Liposomal Irinotecan Not Superior to Topotecan in Phase 3 Trial for Relapsed Small Cell Lung Cancer
No benefit seen for overall survival or progression-free survival, though doubling of objective response rate was seen
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.